Metabo-lipidomics of the Ocular Surface for Cataract Surgery

NCT ID: NCT05802550

Last Updated: 2023-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-04

Study Completion Date

2024-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cataract is the world's leading cause of blindness, the treatment of which, exclusively surgical, offers excellent results in terms of visual recovery. It represents the most frequently performed surgery in France with more than 800,000 procedures each year. However, some patients develop postoperative ocular surface disease that can affect final visual acuity and quality of life. For example, dry eye disease, very common in the elderly, can be worsened by cataract surgery.

The identification of ocular surface biomarkers predictive of the postoperative risk of ocular surface disease carries the promise of better personalized perioperative care.

Conjunctival impression cytology represents a rapid, minimally invasive method of collecting conjunctival cells, which has proven its usefulness in the evaluation of diseases of the ocular surface. The aqueous humor is directly accessible at the beginning of the surgery.

An approach combining ultra-high performance liquid chromatography coupled with high-resolution mass spectrometry on the cells of the ocular surface and on the aqueous humor could improve our understanding of the physiopathology of ocular surface disease following cataract surgery.

This study will aim to 1) search for prognostic biomarkers of ocular surface disease after cataract surgery using a metabo-lipidomic approach 2) improve our understanding of the pathophysiological mechanisms involved.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Age-related Cataract

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Ocular surface Cataract Conjunctival impression cytology Aqueous humor Metabolomic Lipidomic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Longitudinal cohort study in cataract patients

Longitudinal, open-label, single-center cohort study in cataract patients.

Group Type OTHER

Ocular Surface Disease Index

Intervention Type OTHER

Questionnaire on ocular surface disorders

Interferometry

Intervention Type OTHER

Non-contact examination measuring NIBUT (non-invasive break-up time), meibography and tear meniscus measurement

Oxford score

Intervention Type OTHER

Investigation and quantification of superficial corneal punctate keratitis using the Oxford score

Conjunctival collection

Intervention Type OTHER

Two conjunctival prints: one for metabolomic and one for lipidomic

Aqueous humor collection

Intervention Type OTHER

Collection of 0.1 mL of aqueous humor immediately after making the accessory corneal incision at the beginning of the cataract surgery.

Quantification of Tyndall and flare

Intervention Type OTHER

Quantification of Tyndall and flare (from 1 to 4 crosses) in anterior chamber

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ocular Surface Disease Index

Questionnaire on ocular surface disorders

Intervention Type OTHER

Interferometry

Non-contact examination measuring NIBUT (non-invasive break-up time), meibography and tear meniscus measurement

Intervention Type OTHER

Oxford score

Investigation and quantification of superficial corneal punctate keratitis using the Oxford score

Intervention Type OTHER

Conjunctival collection

Two conjunctival prints: one for metabolomic and one for lipidomic

Intervention Type OTHER

Aqueous humor collection

Collection of 0.1 mL of aqueous humor immediately after making the accessory corneal incision at the beginning of the cataract surgery.

Intervention Type OTHER

Quantification of Tyndall and flare

Quantification of Tyndall and flare (from 1 to 4 crosses) in anterior chamber

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with cortico-nuclear and/or subcapsular cataract
* Age \> or = 50 years
* Patient affiliated to a social security system
* Patient agreeing to participate in the study who provided his/her free and informed written consent

Exclusion Criteria

* History of ocular surgery or trauma (≤ 3 months)
* Other types of cataract excepted age-related or diabetic cataract
* Any eye drops or treatments that may interfere with the ocular surface
* Lens wearer
* Any general pathology with a known impact on the ocular surface (auto-immune disease, allergy)
* Proven allergy to povidone-iodine or to a component of the postoperative treatment
* Patient under legal protection (safeguard of justice, curatorship and guardianship), or in a situation of deprivation of freedom
* Patient unable to understand the nature and objectives of the study
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Tours

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

KHANNA

Tours, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

RAOUL KANAV KHANNA

Role: CONTACT

Phone: 02 47 47 27 67

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

RAOUL KANNAV KHANNA, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DR220231

Identifier Type: -

Identifier Source: org_study_id